Get notified when ONCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOncolytics Biotech appoints Stephen Glover to Board, promotes John McAdory to COO
Filed June 2, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
medium
Stephen Glover appointed as ninth independent director. Glover brings 35+ years of biopharma leadership, currently CEO of ZyVersa Therapeutics and former Chairman of Ambrx through its $2B acquisition by Johnson & Johnson.
Item 5.02 verify on EDGAR → -
medium
John McAdory promoted from EVP Strategy and Operations to Chief Operating Officer effective June 1, 2026. McAdory previously led clinical operations at CG Oncology through Phase 3 and IPO. No additional compensation for the new role.
Item 5.02 verify on EDGAR → -
low
Glover granted option to purchase 96,000 shares at June 1 closing price, vesting in three equal annual installments of 32,000 shares contingent on continued board service.
Item 5.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade ONCY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify